Merck drug molnuprivir may develop deadly mutant covid 19 virus when and if available as OTC drugs in LMC countries like in India

The first oral antiviral drug for treatment of COVID-19 developed by Merck, Molnupiravir received approval from UK Medicines and Healthcare products Regulatory Agency on 4 November 2021. But there are some concern about this approval for people who are at high risk of severe COVID -19-associated pneumonia as it can cause more harm than good with the potential of the emergence of new and deadlier variants of SARS-CoV-2. Several virologists and clinicians recommended that molnupiravir is worth trying to preventing severe disease to enable reduction in hospital admission rate and death from COVID-19-associated pneumonia (1) but it is still hypothetical for now till large clinical trials are undertaken.

Content

Author and article information

Journal

Title: Annals of Tropical Medicine & Public Health

Publication date (Electronic): 1 June 2022

Volume: 1

Issue: 1

Affiliations

[1 ] Calcutta School of Tropical Medicine, Kolkata, India

Author notes

[* ]Email: propkb5@ 123456gmail.com .

Author information

Pranab Kumar Bhattacharya https://orcid.org/0000-0001-5430-3814

Article

DOI: 10.36295/ATMPH/2022/0003

SO-VID: 3d968343-43c3-41d6-82a3-b2a99bb6732d

License:

This work has been published open access under Creative Commons Attribution License CC BY 4.0 , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Conditions, terms of use and publishing policy can be found at www.scienceopen.com .

History

Date received : 31 May 2022

Date accepted : 1 June 2022

Data availability: All data generated or analysed during this study are included in this published article (and its supplementary information files).

ScienceOpen disciplines: Infectious disease & Microbiology

Keywords: Molnupivir,COVID-19,Antiviral ,OTC,drug

References

‘Unquestionably a game changer!’ Antiviral pill cuts COVID-19 hospitalization risk. AAAS Articles DO Group. 2021. American Association for the Advancement of Science (AAAS). [Cross Ref]
Pfizer antiviral slashes COVID-19 hospitalizations. AAAS Articles DO Group. 2021. American Association for the Advancement of Science (AAAS). [Cross Ref]
Prakash Hariprasath, Chakrabarti Arunaloke. Global Epidemiology of Mucormycosis. Journal of Fungi. Vol. 5(1)2019. MDPI AG. [Cross Ref]

Comments

Comment on this article

[1] ‘Unquestionably a game changer!’ Antiviral pill cuts COVID-19 hospitalization risk. AAAS Articles DO Group. 2021. American Association for the Advancement of Science (AAAS). [Cross Ref]

[2] Pfizer antiviral slashes COVID-19 hospitalizations. AAAS Articles DO Group. 2021. American Association for the Advancement of Science (AAAS). [Cross Ref]

[3] Prakash Hariprasath, Chakrabarti Arunaloke. Global Epidemiology of Mucormycosis. Journal of Fungi. Vol. 5(1)2019. MDPI AG. [Cross Ref]